Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milrinone SCHEMBL8309385 | 0.76 | PDE3B (0.51) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL2930455 | 0.71 | SQOR (0.48) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL13369870 | 0.71 | PDE3A (0.60) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL27552741 | 0.71 | PDE3A (0.60) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL29409515 | 0.64 | PDE3B (0.51) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL7282577 | 0.64 | CYP2C19 (0.75) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL2932218 | 0.62 | CNR1 (0.49) | CYP2C19SQORCYP1A2CYP2C9NPSR1 | |
| SCHEMBL3841687 | 0.62 | SQOR (0.47) | KDM4EHPGDSQORGCGRMAPK14 | |
| SCHEMBL8111393 | 0.62 | KDM4E (0.45) | PDE3BPDE3ACYP2C19KDM4EPDE5A | |
| SCHEMBL31663627 | 0.62 | CYP2C19 (0.49) | PDE3BPDE3ACYP2C19KDM4EPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046668-A1 | TARGETED INTEGRATION IN MAMMALIAN SEQUENCES ENHANCING GENE EXPRESSION | SELEXIS S.A. (CH) | 2023-02-16 | — | — | US | claimed |
| CN-115151558-A | Targeted integration in mammalian sequences enhances gene expression | 思兰克斯有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20220243228-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | FACTOR BIOSCIENCE INC (US) | 2022-08-04 | — | — | US | claimed |
| US-20260078413-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | FACTOR BIOSCIENCE INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12552793-B2 | Purine derivative and medical use thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-12514861-B2 | Targeting DNA-PKCS and B7-H1 to treat cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| CN-119731177-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4514803-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-119325468-A | Heterocyclic derivatives, compositions and uses thereof | 北京丹擎医药科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119255992-A | Heterocyclic derivatives, compositions and uses thereof | 北京丹擎医药科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4086258-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-11-09 | — | — | EP | disclosed |
| CN-115151558-A | Targeted integration in mammalian sequences enhances gene expression | 思兰克斯有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220243228-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | FACTOR BIOSCIENCE INC (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220220472-A1 | TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-07-14 | — | — | US | disclosed |
| US-11339410-B2 | Methods and products for expressing proteins in cells | FACTOR BIOSCIENCE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339409-B2 | Methods and products for expressing proteins in cells | FACTOR BIOSCIENCE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11332758-B2 | Methods and products for expressing proteins in cells | FACTOR BIOSCIENCE INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11332759-B2 | Methods and products for expressing proteins in cells | FACTOR BIOSCIENCE INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552793-B2 | Purine derivative and medical use thereof | PNP, CYP2D6, ADORA1 | PDE3B 424/4885PDE3A 395/4885CYP2C19 215/4885 |
| US-11332759-B2 | Methods and products for expressing proteins in cells | EIF2AK2, NSUN3, TARBP1 | PDE3B 4464/4885PDE3A 4400/4885CYP2C19 4877/4885 |
| US-11339409-B2 | Methods and products for expressing proteins in cells | EIF2AK2, NSUN3, TARBP1 | PDE3B 4464/4885PDE3A 4400/4885CYP2C19 4877/4885 |
| US-11339410-B2 | Methods and products for expressing proteins in cells | EIF2AK2, NSUN3, TARBP1 | PDE3B 4464/4885PDE3A 4400/4885CYP2C19 4877/4885 |
| US-20260078413-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | APP, SNCA, PSEN2 | PDE3B 3723/4885PDE3A 3125/4885CYP2C19 4613/4885 |
| US-11332758-B2 | Methods and products for expressing proteins in cells | EIF2AK2, NSUN3, TARBP1 | PDE3B 4464/4885PDE3A 4400/4885CYP2C19 4877/4885 |
| US-20220243228-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | EIF2AK2, NSUN3, TARBP1 | PDE3B 4464/4885PDE3A 4400/4885CYP2C19 4877/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | PDE3B 2147/4885PDE3A 1973/4885CYP2C19 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.